The GLP-1 Revolution: Addressing India’s Unique Obesity Crisis
The Arrival of Generic GLP-1s in India As India grapples with its status as the world’s diabetes capital, a new wave of generic GLP-1 receptor agonists has entered the domestic market in 2024, promising to reshape obesity management across the subcontinent. Pharmaceutical manufacturers are rolling out affordable versions of semaglutide and liraglutide, targeting a demographic…